ASPIRE – MTN 020

Links are provided to information about ASPIRE (A Study to Prevent Infection with a Ring for Extended Use), a Phase III safety and effectiveness trial of a vaginal ring containing the antiretroviral drug dapivirine that enrolled 2,629 women at several sites in Africa and was one of two trials of this monthly ring to demonstrate a protective effect against HIV infection. This page also provides links to information about follow-up studies, including HOPE (HIV Open-Label Prevention Extension), and efforts to seek regulatory approval based on the results of ASPIRE and its "sister" study, the Ring Study.

External Links: 
Organization: 
Microbicide Trials Network
Languages: 
English